COMPARING THE EFFECTS OF LOADING DOSE OF ROSUVASTATIN VS ATORVASTATIN ON IMMEDIATE POST-PERFUSION TIMI FLOW IN PRIMARY PCI PATIENT
DOI:
https://doi.org/10.54112/bcsrj.v2023i1.271Keywords:
Multivariable Linear Regression Analysis., Peak CK-MB Levels, ST-Elevation Myocardial Infarction, Randomized Controlled Trial, Atorvastatin, Rosuvastatin, StatinsAbstract
The use of statins in patients undergoing primary percutaneous coronary intervention (PCI) is associated with improved outcomes, but the optimal statin type and loading dose remain unclear. This randomized controlled trial aimed to compare the effects of a loading dose of rosuvastatin versus atorvastatin on immediate post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow and left ventricular ejection fraction (LVEF) at hospital discharge in patients with ST-elevation myocardial infarction (STEMI). 300 patients were enrolled at Mayo Hospital, Lahore, from June 2022 to December 2022. Patients were randomized to receive either a loading dose of rosuvastatin (40 mg) or atorvastatin (80 mg) before primary PCI. There was no significant difference in the proportion of patients achieving TIMI flow grade 3 immediately after PCI between the rosuvastatin and atorvastatin groups (74% vs. 72%, p=0.67). However, the rosuvastatin group had a higher mean LVEF at hospital discharge than the atorvastatin group (55.6% vs. 52.2%, p=0.02) after adjusting for various confounding factors using multivariable linear regression analysis. The two groups had no significant difference in peak CK-MB levels or adverse events. Based on the results, it can be concluded that in patients undergoing primary PCI, there was no significant difference in the proportion of patients achieving TIMI flow grade 3 immediately after PCI between a loading dose of rosuvastatin and atorvastatin.
Downloads
References
Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517-526.
Acharjee S, Moscovitz HC, Banka VS. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Ther. 2005;27:1689-1713.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425.
Adel EM, Elberry AA, Abdel Aziz A, Naguib IA, Alghamdi BS, Hussein RRS. Comparison of the Treatment Efficacy of Rosuvastatin versus Atorvastatin Loading Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. J Clin Med. 2022 Aug 31;11(17):5142. doi: 10.3390/jcm11175142. PMID: 36079090; PMCID: PMC9457390.
Konijnenberg L.S.F., Damman P., Duncker D.J., Kloner R.A., Nijveldt R., van Geuns R.M., Berry C., Riksen N.P., Escaned J., van Royen N. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc. Res. 2020;116:787–805. doi: 10.1093/cvr/cvz301
Hedström E., Åström-Olsson K., Öhlin H., Frogner F., Carlsson M., Billgren T., Jovinge S., Cain P., Wagner G.S., Arheden H. Peak CKMB and cTnT accurately estimates myocardial infarct size after reperfusion. Scand. Cardiovasc. J. 2007;41:44–50. doi: 10.1080/14017430601071849
Ozkalayci F., Türkyılmaz E., Karagoz A., Karabay C.Y., Tanboga İ.H., Oduncu V. A Clinical Score to Predict “Corrected Thrombolysis in Myocardial Infarction Frame Count” in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology. 2021;73:365–373. doi: 10.1177/00033197211045021.
Agrawal V., Sarawag M. Prediction of ST Elevation Resolution on the basis of Time Interval of onset of Chest Pain to Intervention (Total Ischemia Duration) among AMI (Acute myocardial infarction) Patients undergoing PCI (Percutaneous coronary intervention) J. Dent. Med. Sci. 2019;18:7–17.
Clearfield M. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Curr. Atheroscler. Rep. 2010;12:8–10. doi: 10.1007/s11883-009-0083-x.
Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., Di Sciascio G. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial. J. Am. Coll. Cardiol. 2007;49:1272–1278. doi: 10.1016/j.jacc.2007.02.025.
Reindl M., Eitel I., Reinstadler S.J. Role of cardiac magnetic resonance to improve risk prediction following acute ST-elevation myocardial infarction. J. Clin. Med. 2020;9:1041. doi: 10.3390/jcm9041041.
Hedström E., Palmer J., Ugander M., Arheden H. Myocardial SPECT perfusion defect size compared to infarct size by delayed gadolinium-enhanced magnetic resonance imaging in patients with acute or chronic infarction. Clin. Physiol. Funct. Imaging. 2004;24:380–386. doi: 10.1111/j.1475-097X.2004.00579.x.
Penkauskas T., Zentelyte A., Ganpule S., Valincius G., Preta G. Pleiotropic effects of statins via interaction with the lipid bilayer: A combined approach. Biochim. Biophys. Acta (BBA)-Biomembr. 2020;1862:183306. doi: 10.1016/j.bbamem.2020.183306
Kunutsor S.K., Laukkanen J.A. Heart Failure Risk Reduction: Hydrophilic or Lipophilic Statins? Cardiology. 2020;145:384–38
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 M KAMRAN, M MUKHTAR, M ALI, M UMAIR, A AHMED
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
